Seneffekter etter behandling for barnekreft
Rapport/veiledning fra Helsedirektoratet om seneffekter etter kreftbehandling klikk her
Godkjente rehabiliteringsinstitusjoner for rehabilitering etter barnekreftbehandling:
Røde Kors Haugland Rehabiliteringssenter (egne gruppeopphold for barnekreftoverlevere 6-17 år). Lenke
Cato-senteret (diagnoseuavhengig). Lenke
Beitostølen helsesportsenter (>5 år, diagnoseuavhengig). Lenke
Montebellosenteret (for barn under pågående behandling i hovedsak), familieopphold. Lenke
Kortfilm "Det ingen snakker om" om livet etter kreftbehandlingen (NRK, 2023):
NRK TV – Det ingen snakker om
Europeiske anbefalinger for oppfølging av barnekreftoverlevere:
- Balancing the Benefits and Harms of Thyroid Cancer Surveillance in Survivors of Childhood, Adolescent and Young Adult cancer: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration with the PanCareSurFup Consortium. Clement SC, Kremer LCM, et al. Cancer Treat Rev Les her
- Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer. Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. Journal of Clinical Oncology 2016 34:28, 3440-3450 (http://ascopubs.org/doi/full/10.1200/jco.2015.64.3288)
Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Skinner, Roderick et al. The Lancet Oncology , Volume 18 , Issue 2 , e75 - e90 (http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30026-8/fulltext)
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Armenian, Saro H et al. The Lancet Oncology, Volume 16 , Issue 3 , e123 - e136 (http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70409-7/fulltext)
